App-Quantinova.ai

Correlation of merkel virus-specific CD8 T cells with response to immunotherapy in merkel cell carcinoma

T. Pulliam - International Investigative Dermatology/Society for Investigative Dermatology (IID/SID) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Merkel cell carcinoma

Nivolumab

A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

T. Andre - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Colorectal Cancer

Nivolumab

An observational study of health-related quality of life (HRQoL) with electronic patient-reported outcome (ePRO) monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment: NIVO-G QoL study

H. Kawakami - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Nivolumab

Impacts of salvage chemotherapy after nivolumab therapy (NIVO): A REVIVE substudy

H. Matsuoka - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up

L. Shen - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Nivolumab

Efficacy and safety of anti-PD-1 agents in patients with dMMR metastatic solid tumours: A retrospective, real-world study

E. Terán Brage - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Nivolumab

Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)

H. Kawakami - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Nivolumab

Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040

I. Melero - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Nivolumab

Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648

I. Chau - ESMO World Congress on Gastrointestinal Cancer (ESMO GI|ESMO WCGI) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Nivolumab

ENFORTUMAB VEDOTIN-INDUCED DIABETIC KETOACIDOSIS AND AKI: A CASE REPORT

H. Iftikhar - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Advanced Urothelial Carcinoma

Nivolumab

Loss-of-function mutations in PPP2R1A Correlate with Exceptional Survival in Ovarian Clear Cell Carcinomas Treated with Immune Checkpoint Inhibitors

Emily Hinchcliff - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Clear-cell adenocarcinoma

Nivolumab

LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO)

Ana Oaknin - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Adenosquamous carcinoma

Nivolumab

The Genomic Landscape of Vulvovaginal Squamous Cell Carcinoma

John Wallbillich - Society of Gynecologic Oncology (SGO) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma

Nivolumab

Clinical Outcomes in Immunotherapy Induced Pneumonitis

A. E. Davis - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Pulmonary alveolar proteinosis

Nivolumab

A Rare Case of Severe Isolated Enteritis in the Setting of Checkpoint Inhibitor Therapy

R. Ramanathan - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Inflammatory bowel disease

Nivolumab

The Importance of a Multidisciplinary Approach to Lung Cancer Patients in the Era of Immuno-Oncology - A Case Report of Multi-Organ Toxicity with Checkpoint Inhibitor Treatment

S. WEINTRAUB - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Non Small Cell Lung cancer

Nivolumab

Carcinoma of Unknown Primary in the Lung : A Tumor with an Identity Crisis!

R. Padappayil - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic obstructive pulmonary disease

Nivolumab

Immune Checkpoint Inhibitor Related Auto Immune Demyelinating Polyneuropathy

S. A. Mohammed - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Metastatic Renal Cell Cancer

Nivolumab

Concurrent BAP1-Preserved and BAP1-Mutated Malignant Mesothelioma Clones

L. H. Vu - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Coronary Artery Disease

Nivolumab

Ipilimumab/Nivolumab-related orthostatic myoclonus in a patient with metastatic melanoma

B. Green - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Nivolumab

Filters

2342 Abstracts